SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilera, Ximena, Hormazábal, Juan, Vial, Cecilia, Cortes, Lina Jimena, González, Claudia, Rubilar, Paola, Apablaza, Mauricio, Ramírez-Santana, Muriel, Icaza, Gloria, Nuñez-Franz, Loreto, Castillo-Laborde, Carla, Ramírez-Riffo, Carolina, Pérez, Claudia, Quezada-Gate, Rubén, Said, Macarena, Vial, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321248/
https://www.ncbi.nlm.nih.gov/pubmed/35891215
http://dx.doi.org/10.3390/vaccines10071051
Descripción
Sumario:Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.

Ejemplares similares